HuH-7 / HuH-7-luc Orthotopic Mouse Model Service for Liver Cancer

The HuH-7 / HuH-7-luc orthotopic mouse model of liver cancer engrafts a well-differentiated human hepatocellular carcinoma into the hepatic lobe itself, combining true organ-site tumorigenesis with longitudinal luciferase readouts and a sorafenib benchmark that anchors every efficacy result to the field’s reference standard. Alfa Cytology runs this model as a complete preclinical service — from authenticated JCRB0403 banking and luciferase line qualification through intrahepatic implantation (cell suspension or tumor fragment), scheduled whole-body imaging, treatment administration, and endpoints covering tumor burden, metastatic survey, and histopathology.

Overview of HuH-7 / HuH-7-luc Orthotopic Mouse Model for Liver Cancer

HuH-7 is a human hepatocellular carcinoma cell line established in 1982 by Nakabayashi and Sato from the well-differentiated liver tumor of a 57-year-old Japanese male and distributed by the Japanese Collection of Research Bioresources as JCRB0403. The line grows as adherent, epithelial-like cells, is tumorigenic in nude mice, and retains a differentiated hepatocyte program — secreting albumin, fibrinogen, transferrin, lipoproteins, and alpha-fetoprotein, and expressing EpCAM, CD24, and prominin-1 — while carrying a TP53 mutation (Y220C is the commonly reported allele) and active ERK and NF-κB signaling. Beyond oncology, HuH-7 occupies a unique position in virology as the line that fully supports the complete hepatitis C virus life cycle, making it the host cell behind the HCV replicon, HCVcc, and HCVpp systems; that same virological permissiveness, combined with its serum-defined culture adaptability, has sustained more than eight thousand published studies.

Fig 1. Bioluminescence imaging of HuH7-Luc orthotopic liver tumors established by implantation of luciferase-positive tumor blocks, demonstrating therapeutic suppression following CRISPR/Cas9-mediated CDC6 knockout. (Yin, Hang, et al., 2020)

In the orthotopic setting, HuH-7-luc tumors are established in the liver either by direct subcapsular injection of a luciferase-tagged cell suspension or by engrafting small fragments from donor flank tumors, an approach that preserves three-dimensional tumor architecture. Once established, intrahepatic tumors expand within authentic liver perfusion and stromal conditions, and serial bioluminescence imaging after D-luciferin administration tracks burden quantitatively — published calibration data show photon flux from roughly 10⁵ to 10⁹ photons/s/cm²/sr corresponding to tumors from below 1 mm³ up to nearly 2 cm³, a dynamic range that makes early response detection routine. Sorafenib, dosed orally in published orthotopic studies, remains the field’s standard-of-care benchmark against which kinase inhibitors, survivin-targeted agents, and combination regimens are judged on this platform; multimodal BLI-MRI humanized orthotopic variants extend the model for studies requiring anatomical context alongside optical signal.

Cell Line Information: HuH-7 / HuH-7-luc

HuH-7 is among the most cited human liver cancer lines in biomedical research, and its luciferase derivative underpins many imaging-guided orthotopic programs. Core attributes are listed below.

Our Services

A benchmark platform earns its name only when every cohort performs comparably, and that is the standard Alfa Cytology holds for the HuH-7-luc orthotopic program. The team works from authenticated JCRB0403 stocks, keeps passages restrained, and releases HuH-7-luc lines only after uniform in vitro luminescence is confirmed. Implantation — whether cell suspension or donor tumor fragment — follows written technique with defined acceptance checks, imaging runs on fixed calendars matched to the model’s growth tempo, and sorafenib reference arms are available on request. From first baseline scan to the final histopathology slide, Alfa Cytology delivers the HuH-7 / HuH-7-luc orthotopic workflow as one accountable preclinical package.

Workflow of HuH-7 / HuH-7-luc Orthotopic Mouse Model Construction

The HuH-7-luc orthotopic workflow offers two complementary engraftment routes — direct cell injection and fragment transfer — and the same imaging and analysis spine runs beneath both. The sequence below describes the standard construction and study execution flow.

1. Authentication and reporter qualification: HuH-7 / HuH-7-luc stocks are expanded from authenticated JCRB0403 master banks at low passage, mycoplasma-tested, and released after confirming uniform firefly luciferase expression by serial in vitro luminescence assay.
2. Engraftment material preparation: For direct implantation, log-phase cultures are harvested and resuspended at about 2×10⁶ cells in a small-volume PBS (with or without basement-membrane matrix); for fragment transfer, donor flank tumors are grown, excised at defined size, rinsed, and diced into approximately 1 mm³ cubes.
3. Recipient preparation: Female BALB/c nude mice are acclimatized, body-weight stratified, and prepared in a sterile surgical field with anesthesia, analgesia, and thermal support.
4. Intrahepatic implantation: A limited laparotomy exposes the liver; the suspension is microinjected into the subserosa of a hepatic lobe (needle held briefly post-injection to limit reflux) or a tumor fragment is tucked into a shallow hepatic pocket, after which the abdomen is closed in layers.
5. Recovery and baseline imaging: Animals recover under monitoring, and baseline whole-body bioluminescence is acquired after intraperitoneal D-luciferin (150 mg/kg), documenting engraftment and starting photon flux.
6. Longitudinal monitoring and randomized dosing: Imaging repeats on a fixed schedule — often bi-weekly in published designs — alongside body weight and clinical condition; once signals rise steadily, cohorts are randomized with matched burden and treatment begins, with a sorafenib reference arm available for benchmarking.
7. Endpoint analysis: At study end, intrahepatic tumors are excised and weighed, abdominal organs and lungs are inspected and imaged ex vivo, BLI data are normalized to baseline or calibrated against tumor volume, and tissues are processed for H&E histopathology, TUNEL, or marker immunostaining.

Fig 2. HuH-7 / HuH-7-luc orthotopic mouse model construction workflow.

Case Study-HuH-7 / HuH-7-luc Orthotopic Mouse Model Development

Alfa Cytology has executed preclinical programs on the HuH-7 orthotopic platform spanning kinase inhibitors, survivin-pathway agents, and combination regimens, with sorafenib reference arms anchoring cross-study comparability. In these programs, serial bioluminescence imaging tracked intrahepatic tumor growth from engraftment through treatment, dose-response separation was resolved against calibrated photon-flux ranges, and endpoint analyses combined tumor weights with ex vivo organ imaging and histopathological confirmation, including apoptosis readouts where requested. For imaging-focused sponsors, datasets have additionally been structured to support BLI-MRI correlation work. Study parameters and outcomes are maintained as sponsor-specific deliverables, and representative outlines can be shared upon request.

Why Choose Alfa Cytology?

Because HuH-7-luc is the benchmark platform other results are compared against, its execution tolerates no shortcuts. Alfa Cytology’s service pairs authenticated reagents, both orthotopic engraftment techniques, and imaging practice aligned to published calibration standards. Sponsors choose this service for reasons such as:

• Authenticated JCRB0403 stocks at restrained passage with verified luciferase output released into studies.
• Two orthotopic routes — direct subcapsular injection and tumor-fragment transfer — matched to study goals.
• Imaging readouts referenced to published BLI-to-tumor-volume calibration spanning five orders of magnitude.
• Optional sorafenib benchmark arms that place every efficacy result against the field’s reference standard.
• Flexible endpoints from tumor metrics and ex vivo imaging to TUNEL and pathway-marker immunostaining.
• Support for advanced designs, including multimodal BLI-MRI correlation datasets.
• One accountable team with fixed-calendar reporting from implantation through final histopathology.

Contact Us

Ready to benchmark your program on the field’s reference HCC model? Contact us to discuss engraftment route, imaging cadence, and reference-arm design for the HuH-7 / HuH-7-luc orthotopic platform. You can also reach out to Alfa Cytology for a tailored proposal and quotation — our preclinical team will respond with a study plan built around your candidate’s mechanism and timeline.

For research use only. Not intended for any clinical use.